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Abstract

GENETIC VARIATIONS OF CYP2B6 ENZYME AND THE RESPONSE TO
MEPERIDINE IN ORAL SEDATION
by Heath Austin Whitfield D.D.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of
Science in Dentistry at Virginia Commonwealth University.

Virginia Commonwealth University, 2010

Major Director: Tegwyn H. Brickhouse D.D.S., Ph.D
Associate Professor, Department of Pediatric Dentistry

Purpose: The purpose of this study was to determine the relationship of the
CYP2B6 genotype to the clinical response to meperidine in pediatric dental patients.
Methods: Forty-nine patients, ASA I/ II, 41–101 months old, received an oral
sedative regimen containing meperidine for dental treatment. The North Carolina Behavior
Rating Scale (NCBRS) and Overall Effectiveness of Sedation Scale (OESS) were used to
assess their behavior and sedation outcome. Saliva DNA samples were genotyped by PCRRFLP.

Results: We found the following genotype distributions: homozygous wild-type
1*1 (n = 19, 39%), heterozygous 1*6 (n = 25, 51%), and homozygous variant 6*6 (n = 5,
10%). The genotypes showed a significant difference in the North Carolina Behavior
Rating Scores and a trend towards significance of the Overall Effectiveness of Sedation
Scale during meperidine oral sedations.
Conclusion: This research concludes that variations of the CYP2B6 enzyme can be
used in the prediction of successful behaviors for oral sedations that include meperidine in
the drug regimen. Future research regarding the enzyme kinetics of meperidine is needed
to determine the exact enzymatic function of CYP2B6 and its variants.
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INTRODUCTION
According to the American Academy of Pediatric Dentistry (AAPD) moderate
sedation (formerly known as conscious sedation or sedation/analgesia) is defined as
“drug-induced depression of consciousness during which patients respond purposefully to
verbal commands…either alone or accompanied by light tactile stimulation” 1. In 1996, a
survey by Wilson et al of 1758 AAPD members found that 40% of members use sedation
1 to 5 times per week and 20% use sedation more than 5 times per week.2 It is estimated
that more than 1 million children have been sedated by pediatric dentists since 1985.2
Meperidine (Demerol®) is commonly used for moderate sedation in pediatric
dentistry. Meperidine’s popularity in pediatric sedation is due to its fast on-set of
approximately 15 minutes following oral administration. Peak sedation is achieved in
approximately 2 hours and subsides over several hours. 3, 4 Meperidine is an opioid
analgesic that was originally developed as an anticholinergic drug.5, 6 It acts on the mu
() receptors found in the central nervous system (CNS) and on the neural elements in the
bowel.3, 7 Its opioid analgesic properties include inducing sedation, reducing reaction to
painful stimuli and reducing motor activity.3 Meperidine’s side effects include
hypotension, histamine release, nausea and vomiting, and decreased sensitivity to CO2
leading to respiratory depression.4, 7 Meperidine is primarily metabolized in the human
liver by N-demethylation to form the active metabolite normeperidine (6-Ndesmethylmeperidine), which is a potent stimulant of the CNS with no analgesic
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properties.7, 8 The accumulation of normeperidine can cause neurotoxicity and produce
symptoms such as delirium, nervousness, tremor, muscle twitches and seizures.7, 8
Adverse drug reactions (ADRs) are a problem. Annually in the United States just
over 2 million ADRs are estimated to occur, with approximately 100,000 resulting in
death.9 Meperidine may contribute to this problem is some patients. A review of pediatric
dental adverse events and their contributing factors from 1969 through March 20, 1996
by Cote et al. found 95 reported incidents: 51 resulted in death, 9 in permanent
neurologic injury, 21 in prolonged hospital stay without injury and 14 experienced no
harm.10 Twenty-nine of the 60 incidents resulting in death and permanent neurologic
injury were related to various specialties in dentistry. 10
In 2001, Leelataweedwud et al. examined 195 cases of conscious sedation in
pediatric dentistry with the classic triple cocktail of chloral hydrate, meperidine and
hydroxyzine.11 The study found a success rate of 72%, while 23% were unsuccessful and
5% were aborted.11 There were 3% with adverse events reported which included
vomiting, desaturation, prolonged sedation and apneic episodes.11 The incidence of
meperidine ADRs is consistent with genetic variation being a partial causative factor.
Reducing ADRs is especially important when administering drugs to children in
an outpatient setting. Outpatient procedures requiring children to receive sedation include
gastrointestinal procedures, MRI scans, dental rehabilitation, and procedures completed
in the emergency department. The most commonly used opioid analgesics for moderate
sedation and analgesia are fentanyl and meperidine.12 Common adverse effects of these
drugs, when used as single agents can include over-sedation, respiratory depression,
mental clouding, delirium, seizures, hypotension, flushing, sweating and pruritis. While
2

not lethal, these effects are common with and without significant co-morbidities.
Practitioners today are unable to predict, without error, who will and who will not have
an adverse drug reaction. Using pharmacogenomics to select medications could
potentially increase therapeutic responsiveness from the 50% it is today to almost 75%,
while dramatically reducing the number of ADRs occurring each year.13
Pharmacogenetics could revolutionize pediatric sedation, and lead to increased patient
satisfaction and safety.
The cytochrome P450 monooxygenase enzyme group is a multigene family of
hepatic enzymes that are responsible for the oxidative metabolism of most medicines.
Genetic variation in the metabolic activity of these enzymes can have a negative effect on
drug efficacy and safety. Genetic polymorphisms in these and other enzymes can be used
to guide drug treatment. Figure 1 shows the following isoenzymes which are responsible
for the in vitro metabolism of the meperidine: CYP2B6, CYP3A4, and CYP2C19, with
CYP2B6 being the major enzyme that metabolizes meperidine.14 In addition its action in
the liver, CYP2B6 has also been identified in the human brain.15, 16
The CYP2B6 gene is located on chromosome 19, between 19q12 and 19q13.2 and
is composed of 9 exons.17, 18, 19 Haplotype analysis demonstrates the presence of multiple
alleles including the most common form or wild-type CYP2B6*1, and the most common
variant, CYP2B6*6.20 The activity of CYP2B6 varies between individuals and this
variation has been shown to be genetic.14 The diagnostic variant in the haplotype
CYP2B6*6, is a single nucleotide polymorphism of G to T in exon 4 that results in a
substitution of Gln to His at amino acid 172 (516G>T, Gln172His). 21 This change is
associated with a significant loss of function as measured by enzymatic activity.21 This
3

variation is clinically relevant. For example, the CYP2B6*6 variant has been reported to
affect the pharmacokinetics of efavirenz (EFV), a first line medication for treatment of
human immunodeficiency virus (HIV) patients.20, 21 Patients who are homozygous
CYP2B6*6 experience more adverse neurological events such as fatigue and mood
disorders when they are put on long term EFV therapy compared to those who are
homozygous wild type.21
In pediatric dentistry, we often encounter children who are unable to tolerate
dental procedures comfortably despite traditional behavior management techniques and
adequate local anesthesia. These children require sedation in order to receive care.1 This
group of patients, because of their age, is considered more susceptible to the adverse
effects of sedatives and narcotics on the respiratory drive, loss of protective airway
reflexes and airway obstruction.1 Currently, oral sedative agent selection is based on the
patient’s behavior, weight, medical history, physical exam and anticipated duration of the
dental procedures. Structured sedation protocols have shown to reduce morbidities and
enhanced sedation safety for pediatric patients.1 However there remains an element of
unpredictability of response to sedation. One source of variability is thought to be
genetics.
It is unknown at this time what affects the CYP2B6*6 allele may have on the
pharmacokinetics of meperidine. It may be associated with either an increase or decrease
in enzymatic activity, which may have varying clinical effects such as slower drug
clearance, resulting in prolonged sedation, or at the other end of the range excitability.
The specific aim of this study is to determine the relationship between the CYP2B6
genotype at this one loci and behavioral responses to meperidine in pediatric dental
4

patients. A secondary aim was to examine physiological parameters during the oral
sedation according to genotype.
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METHOD AND MATERIALS
Sample and data collection
Forty-nine patients previously identified as requiring oral sedation for dental treatment
were recruited to participate in our research from the VCU School of Dentistry Pediatric Dental
Clinic. Patient ages ranged from 41 to 101 months at the time of treatment. All patients were
ASA I or II. The patients received an oral sedative regimen containing meperidine combined
with one or more of the following medicines: chloral hydrate, hydroxyzine (Vistaril®) and
midazolam (Versed®).
Informed consent for dental treatment under oral sedation, physical restraint and
participation in the study were obtained from the parent/guardian. An assent form was obtained
from patients who were 7 years or older for the saliva collection for CYP2B6 genetic testing.
Saliva has been shown to be a viable and noninvasive method for obtaining DNA for genetic
analysis.22
Prior to the administration of oral sedation medications baseline vital signs were
obtained. After administration of the medications by the treating dental resident, the patients and
their parents/guardian remained in the pre-op room for at least 30 minutes before the start of the
dental procedure. Once in the treatment room, a blood pressure cuff and precordial stethoscope
were applied and the patient was placed on a papoose board. Treatment began once all of the
monitoring equipment was in place and the patient was comfortable. The patient’s heart rate,
blood pressure, and oxyhemoglobin saturation rate (SaO2) were recorded at five minute intervals.
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Respiratory status and breath sounds were monitored throughout the procedure via the precordial
stethoscope by the treating pediatric dental resident.
The behavior of the child during the treatment was recorded using the North Carolina
Behavior Rating Scale (NCBRS) and the overall effectiveness of the sedation was rated using the
Overall Effectiveness of Sedation Scale (OESS).23, 24 Vital signs, physiological parameters and
behavior scores were charted by a monitoring provider. Once the AAPD discharge criteria1 were
met the parents/guardian were escorted into the treatment room to meet the patient. Postoperative instructions were given in verbal and written formats to the patients and their
parents/guardian.
Adverse events were defined as follows: desaturation was when the pulse oximeter, SaO2,
reading was below 95%; apnea was when there was no breath sounds via precordial stethoscope
and no visible sign of chest rise for greater than 25 seconds; excessive sedation was when the
patient required more than 30 minutes to recover; seizure, nausea and vomiting.
Data collection was standardized prior to the start of this research. All nine residents and
full-time faculty at the VCU Pediatric Dental Department were trained and calibrated by
assessing 10 videotaped sedations that were not part of this study. The calibration videos were of
patients of record at VCU Pediatric Dental Department who needed sedation for dental
treatment. Informed consents for videotaping, physical restraint with a papoose board and
standard treatment during oral sedation were obtained from the parent/guardian. The calibration
training entailed watching the videos of 10 taped sedations and assessing each patient’s behavior
based on the North Carolina Behavior Rating Scale (NCBRS) during critical events at every 5
minute intervals (see Appendix 1). The Overall Effectiveness of Sedation Scale (OESS) was used
to rate the overall success of the oral sedation appointment ranging from “successful to
7

unsuccessful” depending on how the patient’s behavior affected the treatment outcome (see
Appendix 1). The calibration study indicated significant agreement (Kappa = 0.60, p < .0001).25

Genetic analysis
For each patient, 2 ml of saliva was collected using Oragen DNA (OG-300) self DNA
collection kit before and after the treatment. The patient’s saliva was collected and the genetic
analysis of CYP2B6 was done at a later date.
The DNA was extracted manually from 2ml of un-induced saliva by using QIAamp DNA
Blood Mini Kit (Valencia, CA, USA), following the manufacturer’s instructions. PCR amplified
the exonic *6 variable region of CYP2B6.21
The genotyping analysis was done with restriction fragment length polymorphism
(RFLP). To generate the CYP2B6 526bp product, the following primers were used: 2B6*6F 5' GGT CTG CCC ATC TAT AAA C - 3' and 2B6*6R 5' - CTG ATT CTT CAC ATG TCT GCG 3'. The PCR product was digested with Fermentas BseNI restriction endonuclease enzyme. The
digestion of the CYP2B6*6 variant allele 516TT amplicons yielded two fragments of 23 and 503
bp and that of the CYP2B6*1 wild type allele 516GG amplicons resulted in 3 fragments of 23,
236 and 267 bp. The digestion products were separated on a 2% agrose gel using electrophoresis,
and banding patterns were visualized under UV light then photo documented.

Statistical Analyses
To compare the observed genotype frequencies with those expected under HardyWeinberg equilibrium, a chi-square test with one degree of freedom was used. The primary aim
was to test the association between CYP2B6 genotypes (homozygous for the normal allele =
8

1*1, heterozygous = 1*6, and homozygous for the variant allele = 6*6) and clinical response
(behavior and sedation effectiveness), using data from the North Carolina Behavior Rating Scale
and the Overall Effectiveness of Sedation Scale.
The groups were compared using a chi-square analysis for nominal outcomes and
analysis of variance (ANOVA) for continuous outcomes. Multivariable analyses were
accomplished using a repeated-measures mixed-model ANOVA (SAS software. JMP8.0 or
SAS9.2, Cary NC). The study was approved by the Virginia Commonwealth University
Institutional Review Board Committee on Investigations Involving Human Subjects. Clinical
data was collected in the VCU Pediatric Dental Clinic and the DNA isolation was performed at
the VCU School of Pharmacy in the laboratory of Dr. Bukaveckas and PGXL Laboratories
(Louisville, KY, USA).
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RESULTS
Preliminary analyses
The demographic characteristics of the patients (n = 49) are shown in Table 1. The
patients were primarily African Americans (n = 32), with 12 Caucasians, 1 Asian and 4 were
marked of other race. There were 28 females and 21 males. The patient’s ages ranged from 41
months to 101 months with an average age of 63.1 months at time of treatment. The majority of
subjects (80%) were ASA I status, while the rest were ASA II. The mean time of treatment
duration was 24.8 minutes with a range of 5 minutes to 63 minutes. The patients were
categorized into three genotypes and identified as: 1*1 for homogenous wild-type allele CYP2B6
(n = 19, 39%), 6*6 for homogenous variant allele (n = 5, 10%), and 1*6 for heterozygous allele
(n = 25, 51%). These proportions were different than the expected values (25%, 50%, 25%, chisquare = 8.02, df = 2, p =0.0181) under the Hardy-Weinberg equilibrium. Comparing the
demographic characteristics in Table 1, there were no significant differences between the
genotypes (ps > 0.09).
The medications used in the patients are described in Table 2. The three drug
combination of meperidine, midazolam, hydroxyzine was used in 57% of the cases. The second
most common drug regimen was meperidine, vistiril, and chloral hydrate, used in 31% of the
cases. The meperidine and midazolam combination was used three times and the meperidine and
hydroxyzine combination was used once. In one case, Propofol® was used by converting to an
intravenous sedation (IVS) due to failed oral sedation.
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In the study cohort (n=49), 49% received restorations (n = 24), 19% extractions (n = 9),
20% both restorations and extractions (n = 10), and in 12% of the cases the planned procedures
were not performed and the process was aborted (n = 6). There were no instances of apnea or
nausea, two instances of vomiting, three instances of desaturation and three instances of excess
sedation meaning the patients too longer than 30 minutes post-op for recovery.

Primary analyses
The primary goal of the study was to compare the North Carolina Behavior Rating Scale
Scores and Overall Effectiveness of Sedation Scores between three genotype groups:
CYP2B6*1*1, CYP2B6*1*6 and CYP2B6*6*6 during oral sedation. The NCBRS was recorded
on 363 occasions (between 0 and 14 times per patient) and had a mean = 1.87, SD = 1.06.
NCBRS was not assessed during the post-operative period. Table 3 shows the Analysis of
NCBRS during the oral sedations. The results of the repeated-measures ANOVA indicated that
NCBRS did vary across event types (p < 0.0001), that the genotypes did not differ (p = 0.0897)
within themselves and that the event differences did not vary within the genotype (p > 0.2, see
Table 4). However, within the Intraoperative measures, the three genotypes were significantly
different (p = 0.0221). Specifically, the 1*1 homozygous wild type’s intraoperative behavior was
significantly different than the 6*6 homozygous variant’s (p = 0.0061) (see Table 3 and Figure
2).
Table 4 shows the number of individuals in each genotype and sedation effectiveness
combination. The genotype groups did not show a statistically significant difference in the
overall effectiveness (Wilcoxon rank-sum chi-square = 5.68, df = 2, p = 0.0585), but a strong
trend towards significance. The overall effectiveness of sedation score may be high for some
11

patients. If the patient was extremely vocal during the procedure, the treating dentist may have
rated the overall sedation in a more negative manner despite the fact the child remained still and
treatment proceeded without complications. However, as may be seen in the table 4, the
CYP2B6*1*1 genotype had the most effective success scores (median effectiveness = 2) while
the homozygous variant, CYP2B6*6 genotype had the worst (median = 4).
A stepwise regression analysis of the demographic characteristics and drug regimens was
performed to determine if the difference between genotypes could also be explained by a
confounding factor. Only Versed (p = 0.0878), Chloral Hydrate (p = 0.0140) and Propofol (p =
0.0088) emerged as potential confounders (using an alpha cut-off of 0.2). There is some
indication of a race difference (p = 0.0741). Including these in the model did not change the
conclusion that overall effectiveness scores did not differ by genotype (p = 0.2980).

Secondary analyses
The secondary analysis focused on outcomes that were assessed on repeated occasions
during the course of each child’s procedure. These outcomes were: HR, Dia-BP, Sys-BP, and
SaO2. Each of these outcomes were analyzed separately with a repeated-measures ANOVA with
the following factors in the model: Event type (Baseline, preOp, IntraOp, and PostOp), genotype
(the three values), and an event*genotype interaction.
The heart rate, (HR) was recorded on 581 occasions (between 2 and 19 times per patient)
and had a mean = 100.4, SD = 19.9. The results of the repeated-measures ANOVA indicated that
HR did vary across event types (p < .0001), that the genotypes did not differ (p > 0.4) and that
the event differences did not vary within genotype (p > 0.4, see Table 6). The estimated mean
heart rate for each event is also shown in Table 6 and Figure 3. Tukey’s HSD indicated that the
12

PreOp mean was not significantly different than any of the others and that each of the others was
significantly different from one another.
The systolic blood pressure (Sys-BP) was recorded on 555 occasions (between 2 and 18
times per patient) and had a mean = 119.7, SD = 19.3. The results of the repeated-measures
ANOVA indicated that Sys-BP did vary across event types (p = .0014), that the genotypes did
not differ (p > 0.7) and that the event differences did not vary within genotype (p > 0.5, see
Table 7). The estimated mean systolic BP for each event is also shown in Table 7 and Figure 4.
Tukey’s HSD indicated that only the IntraOp value was significantly higher than PreOp and
Baseline.
The diastolic blood pressure (Dia-BP) was recorded on 555 occasions (between 2 and 18
times per patient) and had a mean = 67.0, SD = 12.8. The results of the repeated-measures
ANOVA indicated that Dia-BP did vary across event types (p = .0034), that the genotypes did
not differ (p > 0.9) but the event differences did vary with genotype (p = 0.0275, see Table 5).
The estimated mean dia-BP for each event is also shown in Table 8 and Figure 5. Overall,
Tukey’s HSD indicated that the PostOp values were higher than Baseline or PreOp and other
differences were not significant. But, the significant interaction indicates that this pattern may be
different depending upon the genotype. Specifically, there is no difference between the event
types within the 1*1 genotype group (p > 0.5).
The oxygen saturation, SaO2, was recorded on 577 occasions (between 2 and 19 times per
patient) and had a mean = 98.7, SD = 1.4. Since SaO2 was so strongly skewed, with 90% of the
values above 98, this outcome was analyzed on the log-scale and then the summary results back
transformed to the original scale. The results of the repeated-measures ANOVA indicated that
SaO2 did vary across event types (p > 0.0497), that the genotypes did not differ (p > 0.8) and that
13

the event differences did not vary within genotype (p > .9, see Table 9). The estimated mean
SaO2 for each event is also shown in Table 9 and Figure 6. There were three cases where patients
experienced desaturation (<95% SaO2).
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DISCUSSION
Genetic findings:
In vitro studies of CYP2B6 have shown that all variant alleles encode functionally active
proteins.26, 27 The mean protein expression level of those who were heterozygous, 1*6, compared
to that of the wild type, 1*1, did not show a significant reduction (Lang et al 2000). However,
there was a reduction of approximately 50% in protein expression for those who were
homozygous 6*6.26 This was as expected from a clinical efavirenz (EFV) study where they
found that homozygous for the *6 variant allele had more than three-fold higher plasma drug
concentration than those who were wild types.21 In a study by Rodriguez-Novoa et al. 40%
homozygous 6*6 and 19% of heterozygous had EFV concentration >4g/mL, which is the toxic
level. Nearly 20% of homozygous 1*1 and 2% of homozygous 6*6 showed sub therapeutic level
of EVF of <1g/mL.28 The clinical relevance to their research was the individuals who carried
the wild type allele had sub therapeutic concentration of EFV and were at risk for treatment
failure; in contrast, those who were homozygous 6*6 experienced neurological adverse effects
more frequently. As expected, a reduction in enzymatic function was more likely to lead to an
accumulation of EFV plasma concentration within the toxic range.
The homozygous variant CYP2B6*6, homozygous wild-type CYP2B6*1, and
heterozygous CYP2B6 genotypes were present in 10%, 39% and 51% of our population,
respectively. There were no statistical significant differences found between the demographic
characteristics and the genotypes (ps > 0.09).
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Behavioral Findings
Interestingly, our study results showed the opposite of what was expected based on in
vitro studies of CYP2B6 function. There was a statistical significant difference in NCBRS
scores and genotypes during the intraoperative phases of oral sedation (p = 0.0221) (see Table 3).
Specifically, the homozygous wild-type CYP2B6*1 was significantly different than the
homozygous variant CYP2B6*6 as can be seen by observing the 95% CI (p = 0.0061) (see Table
3 and Figure 2). The CYP2B6*1 showed significantly more favorable NCBRS scores than the
CYP2B6?*6 during the intraoperative treatment intervals. This finding is of significant
importance to practitioners in that the success of sedation often depends on behavior at the time
of dental treatment or intraoperative phase.
There was not a statistical significance in OESS outcome, (chi-square = 5.68, df = 2, p =
0.0585) between the genotypes, but a strong trend towards significance. Table 4 showed that the
homozygous wild-type, 1*1, had a median OESS of 2, which translated to a moderately
successful sedation with moderate amount of crying and movement. In patients who were
homozygotes for 6*6, they had a median score of 4 which was interpreted as an unsuccessful
sedation outcome, with continuous crying and movements throughout sedation, treatment
performed with difficulty, and treatment progression was hindered.
One possible explanation to the phenotypes observed in our study was the possibility of
one amino acid substitution of Gln172His mutation caused by natural single-nucleotide
polymorphism enhancing the enzymatic activity of CYP2B6*6. Ariyoshi et al in vitro enzyme
kinetic study demonstrated that wild-type CYP2B6*1 followed the classical hyperbolic
Michaelis-Menten kinetics while the variant allele CYP2B6*6 showed the sigmoidal kinetics
with a higher Vmax value compared to that of the wild-type enzyme.29 Sigmoidal kinetics plot
16

indicates cooperative binding of substrate to the active site which means that the binding of one
substrate molecule affects the binding of subsequent substrate molecules. Allosteric activation by
its substrate, also called homotropic cooperativity, is also seen in CYP3A4 mediated drugs
metabolism.29 This auto activation phenomenon appears dependent on the substrate.29
CYP2B6*6 catalytic activity may be enhanced with meperidine. This would explain the
phenotypes observed in our study population. The patients who were homozygous 6*6 may have
metabolized meperidine at a faster rate, leading to accumulation of normeperidine, which is
associated with symptoms of neurotoxicity and CNS excitation. Furthermore, blood levels of
normeperidine: meperidine AUC ratio is higher when it is delivered orally compared to the
parenteral route.30, 31, 32 While delirium, tremor, muscle twitches and seizures did not occur in the
study, the NCBRS for 4 patients with the variant allele were classified as “wild” meaning defiant
with undesirable behaviors (crying, screaming, head movement, torso movement, hand
movement or foot movement at critical events). Such phenotypes can be interpreted as symptoms
of CNS stimulation by normeperidine. One patient with the variant allele had an NCBRS and
OESS of 1. This patient differed from the other 6*6 patients in that Chloral hydrate was used in
the drug regimen.
It appears that CYP2B6 and its variants activity may be generally predictable by genetic
diagnosis and is dependent upon their substrate. Our research showed that future investigations
will be needed to exactly determine the enzyme CYP2B6*6 properties toward meperidine.
Future studies involve CYP2B6 variants and meperidine pharmacokinetics may help to explain
whether there is an increase in normeperidine concentration in plasma and in peripheral blood
mononuclear cells due to enhanced enzymatic activity caused by auto activation.
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Physiologic findings
In the study population (n=49), 12% were aborted due to the patient’s behaviors. Adverse
events were reported as followed: 3 cases of excessive sedation (>30 minutes for recovery), 2
case of vomiting, and 3 cases of desaturation. There were no instances of apnea or nausea. In
pediatric patients, nausea does not always precede vomit, which could occur instantaneously
without warning.
In oral sedation, pediatric dental patients often cry and struggle during treatment
therefore it is not uncommon to see “false alarms” meaning oxygen desaturation associated with
movements. These “false alarms” should not be overlooked. In oral sedation, desaturation, when
the pulse oximeter reading is <95%, could happen due to many reasons including hypoxia,
hypoventilation, excessive patient movements that cause mechanical interference, or pressure
that the operator exerts on the mandible creating a mechanical airway obstruction. In our study,
the desaturation was found in three cases which was promptly adjusted back to normal readings
of >95% SaO2 saturation after adjusting the position of the mandible and the pulse oximeter
monitor.
Vital signs (heart rate, BP, and SaO2) were not statistically significant between the
different genotypes. The tendency for heart rate and systolic blood pressure to increase with
different event types, such as baseline to intraoperative phase, was seen. Such a finding can be
explained as during intraoperative phase, which was when the patient was stimulated with local
anesthetic injection, rubber dam placement and dental operative procedures, the heart rate could
increase. Of critical importance was the average heart rate, 105.83 beats/minute during the oral
sedation fell within the normal range for children age 3 – 5, which is 80-125 beats/minute. In
addition, the average systolic pressure was 121.18 during the intraoperative phase, which is on
18

the high end of normal limits of systolic pressure for children age 3 – 5, which is 108-121
mmHg.
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CONCLUSION
Many studies have focused on parameters maximizing sedation success while minimizing
ADRs associated with oral sedation medicines. However, at this time, no studies have looked
into the genetic component to oral sedation medicine, specifically meperidine, and the sedation
outcomes. Our research allows for the conclusion that variations of the CYP2B6 enzyme could
predict for successful behavior in oral sedations using meperidine. While meperidine, at the
recommended dosage, is considered safe for oral sedation, the usefulness of CYP2B6 genetic
analysis to personalize medicine may increase patient safety and satisfaction.
Genotyping patients for the variant allele CYP2B6*6 prior to receiving meperidine as an
oral sedative for dental treatment in young children may prove to be important for identifying
individuals with genetic predisposition for sedation failure, unnecessary anesthesia risks,
economical, physical and emotional distress for both the child and the parent. Further research
investigating CYP2B6 and its variants exact enzymatic function with respect to meperidine will
contribute to the clinical significance of this enzyme.
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Table 1: Demographic Characteristics
Characteristic
n
Race
AA
32
Asian
1
C
12
O
4
Ethnicity
B
1
H
2
N
45
Y
1
Gender
F
28
M
21
ASA (1,2)
1
39
2
10
Wt (kg)
Mean
22.0
SD
5.5
Min.
15
Max
38
Duration of tx (min)
Mean
24.8
SD
13.5
Min.
5
Max
63
Age
Mean
4.8
SD
1.1
Min.
3
Max
8
Age (months)
Mean
63.1
SD
12.9
Min.
41
Max
101

%
65
2
24
8
2
4
92
2
57
43
80
20
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Table 2: Medications
Medications
Drug regime
Dem Vis Ver
Dem Vis CH
Dem Ver
Dem Vis
Dem Vis Ver CH Pro
Dem Vis Ver Pro

n

%

28
15
3
1
1
1

57
31
6
2
2
2

Local
none
L+epi
L+epi Sept
Sept

8
19
3
19

16
39
6
39

N2O use
N2O
none

42
7

86
14

Abbreviations: Dem = Demerol, Vis = Vistaril, Ver = Versed, CH = Chloral hydrate, Pro =
Propofol, L = Lidocaine, Sept = Septocaine, N2O = Nitrous oxide.
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Table 3: Analysis of NCBRS

Source
Event
Genotype
Event*Genotype
Event
Genotype 1*1
Baseline
PreOp
IntraOp
Genotype 1*6
Baseline
PreOp
IntraOp
Genotype 6*6
Baseline
PreOp
IntraOp

df Num. df Den.
F p-value
2 308.9 18.42 <.0001
2 52.99 2.524 0.0897
4 308.3 1.343 0.2540
LS Mean

95% CI

1.47
1.49
1.91

1.00
1.02
1.55

1.95
1.96
2.28

1.26
1.44
2.20

0.83
1.02
1.87

1.69
1.87
2.52

2.00
2.40
3.10

1.07
1.47
2.35

2.93
3.33
3.84
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Table 4: Comparing Overall Effectiveness
CYP2B6
genotype
1*1
1*6
6*6

Overall Effectiveness
1
2
3
4 Median
7
5
6
1
2
5
6
5
9
3
1
1
3
4
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Table 5: Analysis of Heart Rate
Source
Event
Genotype
Event*Genotype
Event
Baseline
PreOp
IntraOp
PostOp

df Num. df Den.
F p-value
3 530.40 14.51 <.0001
2 51.63 0.77 0.4686
6 529.80 1.11 0.3568
LS Mean
89.70
94.86
105.83
100.84

SE
3.49
3.65
2.77
2.79

82.80
87.65
100.29
95.25

95% CI
96.61
102.08
111.37
106.43
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Table 6: Analysis of Systolic Blood Pressure
Source
Event
Genotype
Event*Genotype
Event
Baseline
PreOp
IntraOp
PostOp

df Num. df Den.
3 503.30
2 49.84
6 502.80
LS Mean
113.61
112.55
121.18
117.78

SE
3.75
3.54
2.89
2.93

F p-value
5.27 0.0014
0.30 0.7448
0.82 0.5564
95% CI
106.20 121.03
105.55 119.55
115.38 126.97
111.91 123.65
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Table 7: Analysis of Diastolic Blood Pressure
Source
Event
Genotype
Event*Genotype
Event
Baseline
PreOp
IntraOp
PostOp

df Num. df Den.
3 508.20
2 55.48
6 507.80
LS Mean
63.80
63.21
68.05
69.38

SE
2.45
2.27
1.67
1.71

F p-value
4.62 0.0034
0.04 0.9590
2.39 0.0275
95% CI
58.97 68.63
58.72 67.69
64.70 71.39
65.97 72.79
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Table 8: Analysis of Oxygen Saturation
Source
Event
Genotype
Event*Genotype
Event
Baseline
PreOp
IntraOp
PostOp

df Num. df Den.
3 530.40
2 56.68
6 530.40
LS Mean
98.78
98.46
98.49
98.87

F p-value
2.63 0.0497
0.19 0.8265
0.25 0.9599
95% CI
98.27 99.30
97.93 99.00
98.14 98.85
98.51 99.23
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Figure 1. CYP450 isozymes responsible for meperidine metabolism. As illustrated in the figure,
it has been demonstrated in vitro that Cytochrome P450, family 2, subfamily B, polypeptide 6
(CYP2B6) is the enzyme primarily responsible for metabolism of meperidine 14
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Figure 2: NCBRS
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Figure 5: Diastolic Blood Pressure
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APPENDIX A
Behavior rating scales
The North Carolina Behavior Rating Scale and Overall Effectiveness of Sedation Scale
were used to assess clinical response to meperidine and compare the relationship of CYP2B6
genotype and clinical response to meperidine. This appendix serves as a description of these
scales.
North Carolina Behavior Rating Scale (behavior):
The North Carolina Behavior Rating Scale (NCBRS) allows the practitioner and assistant
to assess behavior at critical events of the procedure. Behavior ranging from quiet and
cooperative (1) to wild and defiant (4) is scored at critical events.**
1. Quiet: patient is quiet and/ or sleeping with only extraneous, inconsequential movements
2. Annoyed: patient is cooperative for treatment, but with one or two of the undesirable
behavior*
3. Upset: patient is noticeably disturbed, with two to three undesirable behaviors* making
treatment difficult but possible
4. Wild: patient is extremely defiant with presence of all undesirable behaviors* making
treatment extremely difficult.
* An undesirable behavior includes crying, screaming, head movement, torso movement, hand or
foot movements at critical events**
** Critical events: local anesthetic delivery (L), rubber dam placement (R), operative phase (O)
such as bur penetrating tooth to rubber dam removal and extraction, IV conversion (C).
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Overall Effectiveness of Sedation Scale.
1. Successful: Patient slept throughout procedure with only minimal crying/ movement at
critical events*
2. Moderately successful: Successful sedation with moderate amount of crying and movement
but behavior did not hinder the progress of sedation
3. Mildly successful: Treatment was accomplished as planned, but due to screaming/ combative
movements throughout the sedation; the progression of portions of the treatment were
hindered
4. Unsuccessful: Continuous crying/movement throughout sedation; treatment was performed
with difficulty; the progression of all treatment was hindered
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